Rutgers logo
Rutgers logo
Rutgers logo
Rutgers logo

About Afshin Salsali, MD

Affiliations & Leadership

  • Professor of Medicine, Division of Endocrinology at Rutgers/RWJ Medical School (Volunteer)
  • Medical VP, Diabetes Clinical Development, Novo Nordisk Pharmaceutical Company

Education and Training

  • Board Certified Endocrinologist

Endocrinology fellowship training at University of Vermont (2001-2003)

  • Internal medicine residency at StVincent’s Medical Center, a Columbia University affiliate (1998-2001)
  • Medical degree, Tehran University of Medical Sciences

Select Honors and Awards

  • 2024 Volunteer Faculty Award (Department of Medicine)

Short Biography

After finishing endocrinology fellowship, Dr Salsali stayed at UVM as a junior faculty in the endocrinology department, where he was also in charge of newly started Cystic Fibrosis-Related Diabetes Clinic. Dr Salsali started his research career in drug development by joining Bristol Myers Squibb in 2007 as part of Dapagliflozin (Farxiga) development team. He continued his clinical research journey by joining Boehringer-Ingelheim (BI) in 2012 and his research focus was on the field of diabetes (empagliflozin/Jardiance clinical development), heart failure, and obesity. During his tenure at BI, he was part of part of the EMPAREG outcomes trial, the first ever study showing cardiovascular benefit of a diabetes drug (Jardiance). Dr Salsali joined Novo Nordisk diabetes global development in 2022 as a medical VP. Throughout his drug development career, he has kept his connection with academia by joining Rutgers RWJ Endocrine Division as a clinical volunteer faculty in 2009.

Research/Clinical Interests and Description

Pathophysiology of type 2 diabetes mellitus, monogenic diabetes, testosterone deficiency, subclinical Cushing’s syndrome, primary hyperaldosteronism, and weight management. He is reviewer for several peer-reviewed journals.

Active research and clinical projects

Diabetes Clinical Development

Select Publications